Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab cytokine predictor study in diabetic macular oedema
ACTRN12615000830594Phase 4Completed
- Sponsor
- Centre for Eye Research Australia
- Start
- Sep 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in diabetic macular edema (DME), sponsored by Centre for Eye Research Australia. Primary endpoint: Correlation of aqueous and plasma cytokine concentrations with 12-month change in best-corrected visual acuity. Started Sep 2015; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ACTRN12615000830594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000830594.